Genfit SA
GNFT3.802USD
+0.002+0.05%
Market hours （ET）Quotes delayed by 15 min
190.09MMarket Cap
--P/E TTM
More Details of Genfit SA Company
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Company Info
Ticker SymbolGNFT
Company nameGenfit SA
IPO dateDec 19, 2006
CEOMr. Pascal Prigent
Number of employees180
Security typeOrdinary Share
Fiscal year-endDec 19
AddressParc Eurasante 885 avenue Eugene Avinee
CityLOOS
Stock exchangeEuronext Paris
CountryFrance
Postal code59120
Phone33320164000
Websitehttps://www.genfit.fr/
Ticker SymbolGNFT
IPO dateDec 19, 2006
CEOMr. Pascal Prigent
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Tom Huijbers
Mr. Tom Huijbers
Executive Vice President - Regulatory
Executive Vice President - Regulatory
--
--
Ms. Sandra Silvestri, M.D., Ph.D.
Ms. Sandra Silvestri, M.D., Ph.D.
Director, Representative of IPSEN
Director, Representative of IPSEN
--
--
Dr. Carol Addy, M.D.
Dr. Carol Addy, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Pascal Caisey
Mr. Pascal Caisey
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--
Mr. John Brozek
Mr. John Brozek
Executive Vice President - Data and Information Technology
Executive Vice President - Data and Information Technology
--
--
Mr. Jean-Christophe Marcoux
Mr. Jean-Christophe Marcoux
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
--
--
Dr. Catherine Larue, Ph.D.
Dr. Catherine Larue, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Tom Huijbers
Mr. Tom Huijbers
Executive Vice President - Regulatory
Executive Vice President - Regulatory
--
--
Ms. Sandra Silvestri, M.D., Ph.D.
Ms. Sandra Silvestri, M.D., Ph.D.
Director, Representative of IPSEN
Director, Representative of IPSEN
--
--
Dr. Carol Addy, M.D.
Dr. Carol Addy, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Pascal Caisey
Mr. Pascal Caisey
Chief Operating Officer
Chief Operating Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Millennium Management LLC
0.26%
Morgan Stanley & Co. International Plc
0.05%
AllianceBernstein L.P.
0.04%
Old Mission Capital LLC
0.04%
Optiver Holding B.V.
0.03%
Other
99.57%
Shareholders
Shareholders
Proportion
Millennium Management LLC
0.26%
Morgan Stanley & Co. International Plc
0.05%
AllianceBernstein L.P.
0.04%
Old Mission Capital LLC
0.04%
Optiver Holding B.V.
0.03%
Other
99.57%
Shareholder Types
Shareholders
Proportion
Hedge Fund
0.29%
Investment Advisor
0.08%
Investment Advisor/Hedge Fund
0.06%
Research Firm
0.05%
Other
99.53%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
22
237.41K
0.47%
-565.92K
2025Q1
25
259.00K
0.52%
-1.29M
2024Q4
26
260.49K
0.52%
-1.21M
2024Q3
28
127.35K
0.26%
-1.36M
2024Q2
31
97.15K
0.20%
-1.36M
2024Q1
31
97.93K
0.20%
-1.42M
2023Q4
31
648.17K
1.30%
-1.34M
2023Q3
32
1.16M
2.33%
-1.43M
2023Q2
30
1.77M
3.54%
-496.41K
2023Q1
30
2.19M
4.39%
-60.89K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Millennium Management LLC
131.48K
0.26%
-34.89K
-20.97%
Mar 31, 2025
Morgan Stanley & Co. International Plc
25.52K
0.05%
-9.20K
-26.50%
Mar 31, 2025
AllianceBernstein L.P.
22.36K
0.04%
+13.38K
+148.94%
Jun 30, 2024
Old Mission Capital LLC
22.24K
0.04%
+22.24K
--
Mar 31, 2025
Optiver Holding B.V.
13.15K
0.03%
+12.89K
+4845.49%
Mar 31, 2025
Citadel Advisors LLC
12.33K
0.02%
+12.33K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
3.21K
0.01%
--
--
May 31, 2025
UBS Financial Services, Inc.
3.12K
0.01%
+70.00
+2.30%
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
678.00
0%
--
--
Mar 31, 2025
Qube Research & Technologies Ltd
--
0%
-98.00
-100.00%
Sep 30, 2024
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
